Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).

Lüftner D, Bauerfeind I, Braun M, Brucker SY, Fasching PA, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Thill M.

Breast Care (Basel). 2019 Oct;14(5):315-324. doi: 10.1159/000502603. Epub 2019 Sep 17. Review.

PMID:
31798392
2.

Re-Excision Rates in Breast-Conserving Surgery for Invasive Breast Cancer after Neoadjuvant Chemotherapy with and without the Use of a Radiopaque Tissue Transfer and X-ray System.

Jamaris S, Akpolat-Basci L, Stephanou M, Wetzig S, Cubuk Y, Gerharz J, Bittner AK, See MH, Liedtke C, Kolberg HC.

Breast Care (Basel). 2019 Oct;14(5):302-307. doi: 10.1159/000493017. Epub 2018 Nov 14.

PMID:
31798390
3.

Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.

Welslau M, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Kolberg HC, Nabieva N, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Schneeweiss A, Fehm TN.

Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099. doi: 10.1055/a-1001-9952. Epub 2019 Oct 22.

4.

Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.

Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V.

Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089. doi: 10.1055/a-1001-9925. Epub 2019 Oct 22.

5.

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.

Kolberg HC, Colleoni M, Santi P, Demetriou GS, Segui-Palmer MA, Fujiwara Y, Hurvitz SA, Hanes V.

Target Oncol. 2019 Dec;14(6):647-656. doi: 10.1007/s11523-019-00675-z. Review.

6.

Targeted Intraoperative Radiotherapy During Breast-conserving Surgery for Breast Cancer in Patients After Implant Augmentation.

Kolberg HC, Uhl V, Massarut S, Holmes D, Kolberg-Liedtke C, Kelly EW, Lövey G, Vaidya JS.

Anticancer Res. 2019 Aug;39(8):4215-4218. doi: 10.21873/anticanres.13582.

PMID:
31366508
7.

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.

Wallwiener M, Nabieva N, Feisst M, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Popovic M, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Schmidt K, Belleville E, Brucker SY, Hadji P, Beckmann MW, Wallwiener D, Kümmel S, Hartkopf A, Fasching PA.

BMC Cancer. 2019 Jun 21;19(1):611. doi: 10.1186/s12885-019-5806-y.

8.

Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019).

Untch M, Thomssen C, Bauerfeind I, Braun M, Brucker SY, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Lüftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching PA, Harbeck N.

Geburtshilfe Frauenheilkd. 2019 Jun;79(6):591-604. doi: 10.1055/a-0897-6457. Epub 2019 Jun 14.

9.

Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel.

Kolberg HC, Schneeweiss A, Fehm TN, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux MP, Janni W, Hartkopf AD, Taran FA, Wallwiener M, Overkamp F, Tesch H, Ettl J, Lüftner D, Müller V, Schütz F, Fasching PA, Brucker SY.

Geburtshilfe Frauenheilkd. 2019 May;79(5):470-482. doi: 10.1055/a-0887-0861. Epub 2019 May 21.

10.

Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer.

Schäfer SA, Hülsewig C, Barth P, von Wahlde MK, Tio J, Kolberg HC, Bernemann C, Blohmer JU, Kiesel L, Kolberg-Liedtke C.

Future Oncol. 2019 Jun;15(16):1921-1938. doi: 10.2217/fon-2018-0564. Epub 2019 May 29.

PMID:
31140870
11.

Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.

Nabieva N, Häberle L, Brucker SY, Janni W, Volz B, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kuemmel S, Martin B, Thomssen C, Graf H, Wolf C, Lux MP, Bayer CM, Rauh C, Hack CC, Almstedt K, Gass P, Heindl F, Brodkorb T, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Rack B, Beckmann MW, Fehm T, Rody A, Maass N, Hein A, Fasching PA.

Int J Cancer. 2019 Oct 15;145(8):2114-2121. doi: 10.1002/ijc.32294. Epub 2019 Apr 2.

PMID:
30901076
12.

Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.

Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Ettl J.

Geburtshilfe Frauenheilkd. 2019 Mar;79(3):268-280. doi: 10.1055/a-0842-6661. Epub 2019 Mar 12.

13.

Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer.

Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Nabieva N, Taran FA, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Overkamp F, Schneeweiss A, Tesch H.

Geburtshilfe Frauenheilkd. 2019 Mar;79(3):256-267. doi: 10.1055/a-0842-6614. Epub 2019 Mar 12.

14.

Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars.

Kolberg HC, von Minckwitz G, Hanes V.

Oncotarget. 2019 Jan 1;10(1):8-9. doi: 10.18632/oncotarget.26528. eCollection 2019 Jan 1. No abstract available.

15.

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.

Wunderle M, Pretscher J, Brucker SY, Volz B, Hartmann A, Fiessler C, Hein A, Häberle L, Jud SM, Lux MP, Janni W, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kümmel S, Martin B, Thomssen C, Graf H, Wolf C, Bayer CM, Hack CC, Almstedt K, Gass P, Heindl F, Brodkorb TF, Nabieva N, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Wallwiener D, Rack B, Fehm T, Rody A, Maass N, Beckmann MW, Fasching PA, Rauh C.

Breast Cancer Res Treat. 2019 Apr;174(2):453-461. doi: 10.1007/s10549-018-05115-6. Epub 2019 Jan 2.

PMID:
30603996
16.

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.

Lux MP, Nabieva N, Hartkopf AD, Huober J, Volz B, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Schneeweiss A, Brucker SY.

Cancers (Basel). 2018 Dec 21;11(1). pii: E10. doi: 10.3390/cancers11010010.

17.

Translational highlights in breast cancer research and treatment: recent developments with clinical impact.

Fasching PA, Schneeweiss A, Kolberg HC, Ettl J, Fehm TN, Overkamp F, Lüftner D.

Curr Opin Obstet Gynecol. 2019 Feb;31(1):67-75. doi: 10.1097/GCO.0000000000000510. Review.

PMID:
30520757
18.

Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer.

Müller V, Wöckel A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Hadji P, Tesch H, Ettl J, Lüftner D, Welslau M, Belleville E, Brucker SY, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Schneeweiss A, Overkamp F.

Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1119-1128. doi: 10.1055/a-0715-2899. Epub 2018 Nov 26.

19.

Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer.

Wöckel A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Welslau M, Belleville E, Brucker SY, Schütz F, Fasching PA, Fehm TN, Schneeweiss A, Kolberg HC.

Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1110-1118. doi: 10.1055/a-0715-2821. Epub 2018 Nov 26.

20.

Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST).

Liedtke C, Kolberg HC, Kerschke L, Görlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Stäbler A, Schmatloch S, Hausschild M, Schwentner L, von Minckwitz G, Loibl S, Untch M, Kühn T.

Clin Exp Metastasis. 2018 Dec;35(8):777-783. doi: 10.1007/s10585-018-9938-2. Epub 2018 Oct 15.

PMID:
30324492
21.

Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.

Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lüftner D, Wallwiener M, Müller V, Janni W, Fehm TN, Schneeweiss A, Untch M, Pott D, Lux MP, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann MW, Brucker SY, Kolberg HC.

Breast Cancer Res Treat. 2019 Jan;173(2):319-328. doi: 10.1007/s10549-018-5008-3. Epub 2018 Oct 15.

PMID:
30324275
22.

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians.

Gass P, Untch M, Müller V, Möbus V, Thomssen C, Häberle L, Erber R, Hein A, Jud SM, Lux MP, Hack CC, Hartmann A, Kolberg HC, Ettl J, Lüftner D, Jackisch C, Beckmann MW, Janni W, Schneeweiss A, Fasching PA, Nabieva N.

Geburtshilfe Frauenheilkd. 2018 Jul;78(7):707-714. doi: 10.1055/a-0642-9462. Epub 2018 Jul 25.

23.

Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.

von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, Zhang N, Hanes V.

Lancet Oncol. 2018 Jul;19(7):987-998. doi: 10.1016/S1470-2045(18)30241-9. Epub 2018 Jun 4.

PMID:
29880292
24.

RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients.

Keup C, Mach P, Aktas B, Tewes M, Kolberg HC, Hauch S, Sprenger-Haussels M, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2018 Jul;64(7):1054-1062. doi: 10.1373/clinchem.2017.283531. Epub 2018 May 16.

25.

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.

Nabieva N, Fehm T, Häberle L, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Popovic M, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Hack CC, Schmidt K, Belleville E, Brucker SY, Kümmel S, Beckmann MW, Wallwiener D, Hadji P, Fasching PA.

Eur J Cancer. 2018 Jun;96:82-90. doi: 10.1016/j.ejca.2018.03.020. Epub 2018 Apr 18.

PMID:
29679775
26.

Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.

Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.

Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.

27.

Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.

Taran FA, Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Fasching PA, Fehm TN, Schütz F.

Geburtshilfe Frauenheilkd. 2018 Mar;78(3):237-245. doi: 10.1055/s-0044-101613. Epub 2018 Mar 21.

28.

Update Breast Cancer 2017 - Implementation of Novel Therapies.

Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Huober JB, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Fasching PA.

Geburtshilfe Frauenheilkd. 2017 Dec;77(12):1281-1290. doi: 10.1055/s-0043-122885. Epub 2017 Dec 18.

29.

Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.

Müller V, Nabieva N, Häberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Lüftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm TN, Brucker SY, Wallwiener D, Schneeweiss A, Wallwiener M.

Breast. 2018 Feb;37:154-160. doi: 10.1016/j.breast.2017.08.008. Epub 2017 Dec 10.

PMID:
29237546
30.

Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer.

Kolberg HC, Lövey G, Akpolat-Basci L, Stephanou M, Fasching P, Untch M, Hoffmann O, Bulsara M, Vaidya J, Liedtke C.

Breast Care (Basel). 2017 Oct;12(5):318-323. doi: 10.1159/000479424. Epub 2017 Sep 21.

31.

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.

Hartkopf AD, Huober J, Volz B, Nabieva N, Taran FA, Schwitulla J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lux MP, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A.

Breast. 2018 Feb;37:42-51. doi: 10.1016/j.breast.2017.10.002. Epub 2017 Oct 26.

PMID:
29100043
32.

Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.

Nabieva N, Kellner S, Fehm T, Häberle L, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Brucker SY, Kümmel S, Beckmann MW, Wallwiener D, Hadji P, Fasching PA.

Ann Oncol. 2018 Jan 1;29(1):186-192. doi: 10.1093/annonc/mdx630.

PMID:
29045642
33.

An Ultralow-Dose 1-Day Protocol With Activities Lower Than 20 MBq for the Detection of Sentinel Lymph Nodes in Breast Cancer-Experiences After 150 Cases.

Kolberg HC, Afsah S, Kuehn T, Winzer U, Akpolat-Basci L, Stephanou M, Wetzig S, Hoffmann O, Liedtke C.

Technol Cancer Res Treat. 2017 Jan 1:1533034617728862. doi: 10.1177/1533034617728862. [Epub ahead of print]

34.

Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry.

Wallwiener M, Heindl F, Brucker SY, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Rauh C, Blum S, Nabieva N, Brodkorb TF, Faschingbauer C, Langemann H, Schulmeyer C, Volz B, Rübner M, Lüftner D, Müller V, Belleville E, Janni W, Fehm TN, Wallwiener D, Ganslandt T, Beckmann MW, Schneeweiss A, Fasching PA, Gass P.

Geburtshilfe Frauenheilkd. 2017 Aug;77(8):870-878. doi: 10.1055/s-0043-116223. Epub 2017 Aug 24.

35.

Editorial: Primary Systemic Therapy for Breast Cancer.

Kolberg HC.

Rev Recent Clin Trials. 2017;12(2):66. doi: 10.2174/157488711202170510202553. No abstract available.

PMID:
28825398
36.

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.

Bredemeier M, Kasimir-Bauer S, Kolberg HC, Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M, Kimmig R, Aktas B.

Mol Med Rep. 2017 May;15(5):2957-2968. doi: 10.3892/mmr.2017.6415. Epub 2017 Mar 30.

37.

Breast cancer and genomic testing.

Liedtke C, Kolberg HC.

Br J Surg. 2017 Jun;104(7):799-801. doi: 10.1002/bjs.10513. Epub 2017 Mar 16. No abstract available.

PMID:
28300277
38.

Transvaginal PVDF-mesh for cystocele repair: A cohort study.

Barski D, Arndt C, Gerullis H, Yang J, Boros M, Otto T, Kolberg HC.

Int J Surg. 2017 Mar;39:249-254. doi: 10.1016/j.ijsu.2017.02.006. Epub 2017 Feb 10.

39.

Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.

Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching PA, Untch M, Bulsara M, Vaidya JS, Liedtke C.

Rev Recent Clin Trials. 2017;12(2):93-100. doi: 10.2174/1574887112666170201142458.

PMID:
28155607
40.

Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.

Kolberg HC, Aktas B, Liedtke C.

Rev Recent Clin Trials. 2017;12(2):67-72. doi: 10.2174/1574887112666170201143321. Review.

PMID:
28155606
41.

Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.

Kolberg HC, Akpolat-Basci L, Stephanou M, Aktas B, Hannig CV, Liedtke C.

Breast Care (Basel). 2016 Oct;11(5):323-327. Epub 2016 Oct 24.

42.

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.

Gaß P, Fasching PA, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Beckmann MW, Wallwiener D, Kümmel S, Löhberg CR.

Breast Care (Basel). 2016 Oct;11(5):315-322. Epub 2016 Oct 27.

43.

Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy.

Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching PA, Untch M, Liedtke C, Bulsara M, Vaidya JS.

Strahlenther Onkol. 2017 Jan;193(1):62-69. doi: 10.1007/s00066-016-1072-y. Epub 2016 Nov 17.

PMID:
27858093
44.

Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.

Waldrep AR, Avery EJ, Rose FF Jr, Midathada MV, Tilford JA, Kolberg HC, Hutchins MR.

Anticancer Res. 2016 Oct;36(10):5389-5395.

PMID:
27798904
45.

Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts.

Liedtke C, Kolberg HC.

Breast Care (Basel). 2016 Aug;11(4):275-281. Epub 2016 Jul 28. Review.

46.

Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.

Hack CC, Fasching PA, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Wallwiener D, Kümmel S, Beckmann MW, Paepke D.

Integr Cancer Ther. 2017 Jun;16(2):165-175. doi: 10.1177/1534735416668575. Epub 2016 Sep 14.

47.

Indications for Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).

De Luca M, Angrisani L, Himpens J, Busetto L, Scopinaro N, Weiner R, Sartori A, Stier C, Lakdawala M, Bhasker AG, Buchwald H, Dixon J, Chiappetta S, Kolberg HC, Frühbeck G, Sarwer DB, Suter M, Soricelli E, Blüher M, Vilallonga R, Sharma A, Shikora S.

Obes Surg. 2016 Aug;26(8):1659-96. doi: 10.1007/s11695-016-2271-4. No abstract available.

48.

Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.

Hein A, Gass P, Walter CB, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Wuerstlein R, Lounsbury D, Lux MP, Lüftner D, Wallwiener M, Müller V, Belleville E, Janni W, Fehm TN, Wallwiener D, Ganslandt T, Ruebner M, Beckmann MW, Schneeweiss A, Fasching PA, Brucker SY.

Breast Cancer Res Treat. 2016 Jul;158(1):59-65. doi: 10.1007/s10549-016-3850-8. Epub 2016 Jun 9.

PMID:
27283834
49.

Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer.

Liedtke C, Kolberg HC.

Viszeralmedizin. 2015 Dec;31(6):424-32. doi: 10.1159/000441961. Epub 2015 Dec 3. Review.

50.

Relatedness predicts multiple measures of investment in cooperative nest construction in sociable weavers.

Leighton GM, Echeverri S, Heinrich D, Kolberg H.

Behav Ecol Sociobiol. 2015 Nov 1;69(11):1835-1843. Epub 2015 Aug 29.

Supplemental Content

Loading ...
Support Center